Editas Medicine Inc (EDIT)

Currency in USD
1.82
+0.16(+9.61%)
Closed·
1.81-0.01(-0.55%)
·
Earnings results expected in 11 days
EDIT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.731.85
52 wk Range
0.914.54
Key Statistics
Prev. Close
1.67
Open
1.78
Day's Range
1.73-1.85
52 wk Range
0.91-4.54
Volume
1.93M
Average Volume (3m)
1.77M
1-Year Change
45.6%
Book Value / Share
0.15
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EDIT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.43
Upside
+198.27%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Editas Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Editas Medicine Inc Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc SWOT Analysis


Gene Editing Pionee
Editas Medicine leads in CRISPR/Cas9 technology, developing transformative therapies for genetic disorders with a focus on in vivo genome editing
Financial Crossroads
Despite a $256M market cap and cash runway into 2027, Editas faces challenges with negative EPS forecasts and substantial R&D investments
Pipeline Potential
Explore Editas' progress towards declaring two development candidates by mid-2025, including programs for Sickle Cell Disease and liver targets
Market Outlook
Analysts maintain a cautious stance, with price targets ranging from $3 to $4, reflecting the complex landscape of gene editing therapeutics
Read full SWOT analysis

Compare EDIT to Peers and Sector

Metrics to compare
EDIT
Peers
Sector
Relationship
P/E Ratio
−0.9x−1.2x−0.5x
PEG Ratio
−0.110.090.00
Price/Book
13.2x1.8x2.6x
Price / LTM Sales
3.8x105.1x3.3x
Upside (Analyst Target)
174.7%540.6%45.8%
Fair Value Upside
Unlock12.0%6.4%Unlock

Analyst Ratings

6 Buy
6 Hold
2 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.43
(+198.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Clear Street
Buy4.60+152.75%4.00MaintainNov 10, 2025
H.C. Wainwright
Buy5.00+174.73%-MaintainSep 05, 2025
Wells Fargo
Hold4.00+119.78%3.00MaintainSep 03, 2025
Evercore ISI
Buy4.00+119.78%-New CoverageAug 25, 2025
H.C. Wainwright
Buy5.00+174.73%3.00MaintainAug 15, 2025

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
-0.28 / -0.30
Revenue / Forecast
7.54M / 4.94M
EPS Revisions
Last 90 days

EDIT Income Statement

People Also Watch

1.820
PACB
+6.12%
3.160
ABCL
+13.67%
4.87
ALT
-1.02%
3.230
EVGO
+11.00%
95.08
AKAM
+3.92%

FAQ

What Is the Editas Medicine (EDIT) Stock Price Today?

The Editas Medicine stock price today is 1.82

What Stock Exchange Does Editas Medicine Trade On?

Editas Medicine is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Editas Medicine?

The stock symbol for Editas Medicine is "EDIT."

What Is the Editas Medicine Market Cap?

As of today, Editas Medicine market cap is 177.67M.

What Is Editas Medicine's Earnings Per Share (TTM)?

The Editas Medicine EPS (TTM) is -2.35.

When Is the Next Editas Medicine Earnings Date?

Editas Medicine will release its next earnings report on Feb 19, 2026.

From a Technical Analysis Perspective, Is EDIT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Editas Medicine Stock Split?

Editas Medicine has split 0 times.

How Many Employees Does Editas Medicine Have?

Editas Medicine has 246 employees.

What is the current trading status of Editas Medicine (EDIT)?

As of Feb 08, 2026, Editas Medicine (EDIT) is trading at a price of 1.82, with a previous close of 1.67. The stock has fluctuated within a day range of 1.73 to 1.85, while its 52-week range spans from 0.91 to 4.54.

What Is Editas Medicine (EDIT) Price Target According to Analysts?

The average 12-month price target for Editas Medicine is USD5.43, with a high estimate of USD13 and a low estimate of USD1. 6 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +198.27% Upside potential.

What Is the EDIT Premarket Price?

EDIT's last pre-market stock price is 1.79. The pre-market share volume is 184,240.00, and the stock has decreased by 0.12, or 7.19%.

What Is the EDIT After Hours Price?

EDIT's last after hours stock price is 1.81, the stock has decreased by -0.01, or -0.55%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.